Potential Bargains
These companies are trading below what experts believe they're truly worth. Our analysts have carefully selected stocks with significant upside potential, representing hidden opportunities for growth as they move toward their projected valuations.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
ProMIS Neurosciences Inc
PMN
Current price
$0.85
This clinical-stage biotech company is considered undervalued due to the high-risk, high-reward nature of its therapeutic developments targeting neuro...
This clinical-stage biotech company is considered undervalued due to the high-risk, high-reward nature of its therapeutic developments targeting neurodegenerative diseases.
Star Equity Holdings Inc
STRR
Current price
$2.07
As a diversified holding company, its current market price may not reflect the combined value of its assets across building solutions, energy, and inv...
As a diversified holding company, its current market price may not reflect the combined value of its assets across building solutions, energy, and investments.
SILVACO GROUP
SVCO
Current price
$4.63
Specializing in semiconductor design software, this company is viewed by analysts as a bargain due to its potential for growth as chip complexity incr...
Specializing in semiconductor design software, this company is viewed by analysts as a bargain due to its potential for growth as chip complexity increases.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
This collection captures the essence of value investing—buying quality assets at a discount to their intrinsic value. We've identified companies where there's a substantial gap between current price and analyst targets, suggesting significant growth potential as the market eventually recognizes their true worth.
What You Need to Know
These stocks come from diverse sectors including technology, biotechnology, and cyclical industries that may be temporarily out of favor. While they offer higher-reward opportunities, they can also carry more risk as the market may take time to recognize their potential value.
Why These Stocks
Each company was selected based on strong analyst "Buy" ratings and a substantial difference between current trading price and future valuation estimates. They represent businesses with strong fundamentals that financial experts believe the market has overlooked or undervalued.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+310.85%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 310.85% over the next year.
Stocks Rated Buy by Analysts
15 of 15 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 4.3% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
Hidden Value Waiting to Be Discovered
These companies are flying under the radar with strong fundamentals that the market hasn't fully recognized yet. Getting in now could mean significant returns when others finally catch on.
Potential for Dramatic Price Corrections
When undervalued stocks finally get the attention they deserve, price movements can happen quickly. Analysts believe these companies could see substantial growth as they move toward their true valuations.
Expert-Backed Opportunities
These aren't random picks—each stock has been identified by market professionals as trading below its intrinsic value, giving you confidence that you're investing based on expert analysis.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.